Millipore CorporationMIL

Morningstar Rating

Stock Research and Analysis

by Meera Venu

Once known solely for its filtration technology, Millipore has expanded its portfolio to offer solutions for a variety of processes in scientific research and drug development. By focusing on niches with high switching costs and high barriers to entry, Read more

Bulls Say

Millipore's research products improve the speed, accuracy, and cost of experiments. These products offer improved solutions and service for scientists in Millipore's areas of focus.

Investments in or approval for biosimilar drugs could increase demand for Millipore's products. Biosimilars would need the same consumables for manufacturing processes as their biologic counterparts.

Manufacturing issues at Genzyme GENZ highlight the need to have effective quality and process-monitoring procedures. Millipore's products can help firms seeking to improve these processes. Read more

Bears Say

Some of Millipore's competitors have broader life science offerings. Customers preferring a one-stop shop may opt to do business with them instead of Millipore.

Demand for Millipore's products can vary with customers' research budgets and inventory levels. If customers cut budgets or build excess inventory, demand for the firm's consumables can slow.

Unlike some of its instrument-heavy competitors, Millipore will likely receive less of a positive impact from NIH stimulus funding expected in 2010. Read more

Strategy

Millipore has narrowed its focus to the bioprocess and bioscience segments in the life sciences market. The firm seeks to strengthen its position within these niches by developing products in highly Read more

Management

We think Millipore has good stewards at its helm and give the firm a B Stewardship Grade. Martin Madaus has served as Millipore's CEO and chairman for four years. Madaus brings executive experience from Roche Diagnostics. We applaud his change of company Read more

Profile

Founded in 1954, Millipore develops and sells tools and services for the life science and biopharmaceutical markets. The firm's bioprocess segment constitutes about 55% Read more

First Name

Last Name

Email Address

Zip Code

Create Password

Verify Password

(6-15 characters; case sensitive)

What is your occupation or job title?

Select...

Your registration indicates agreement to the terms of use.

Dodge & Cox: Valuations Attractive in Technology
Watch more